- Home
- PHYS vs QGEN Comparison
PHYS vs QGEN Comparison
Compare PHYS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHYS
- QGEN
- Stock Information
- Founded
- PHYS N/A
- QGEN 1986
- Country
- PHYS
- QGEN Netherlands
- Employees
- PHYS N/A
- QGEN N/A
- Industry
- PHYS
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHYS
- QGEN Health Care
- Exchange
- PHYS NYSE
- QGEN Nasdaq
- Market Cap
- PHYS 8.5B
- QGEN 9.5B
- IPO Year
- PHYS N/A
- QGEN 1996
- Fundamental
- Price
- PHYS $20.20
- QGEN $44.67
- Analyst Decision
- PHYS
- QGEN Buy
- Analyst Count
- PHYS 0
- QGEN 9
- Target Price
- PHYS N/A
- QGEN $51.42
- AVG Volume (30 Days)
- PHYS N/A
- QGEN 865.8K
- Earning Date
- PHYS N/A
- QGEN 02-04-2025
- Dividend Yield
- PHYS N/A
- QGEN 2.96%
- EPS Growth
- PHYS N/A
- QGEN N/A
- EPS
- PHYS N/A
- QGEN 0.41
- Revenue
- PHYS N/A
- QGEN $1,966,174,000.00
- Revenue This Year
- PHYS N/A
- QGEN $2.78
- Revenue Next Year
- PHYS N/A
- QGEN $5.69
- P/E Ratio
- PHYS N/A
- QGEN $107.74
- Revenue Growth
- PHYS N/A
- QGEN 0.62
- 52 Week Low
- PHYS N/A
- QGEN $39.03
- 52 Week High
- PHYS N/A
- QGEN $47.44
- Technical
- Relative Strength Index (RSI)
- PHYS 45.98
- QGEN 54.59
- Support Level
- PHYS $20.17
- QGEN $44.02
- Resistance Level
- PHYS $20.98
- QGEN $46.08
- Average True Range (ATR)
- PHYS 0.16
- QGEN 0.76
- MACD
- PHYS -0.03
- QGEN -0.03
- Stochastic Oscillator
- PHYS 27.98
- QGEN 41.98
About PHYS SPROTT PHYSICAL GOLD TRUST
Sprott Physical Gold Trust is a closed-end mutual fund trust. The company provides a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical gold bullion without the inconvenience associated with direct investment in physical gold bullion. The company invests mainly in long-term holdings of unencumbered, fully allocated, physical gold bullion and does not and will not speculate about short-term changes in gold prices.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).